SAN DIEGO--(BUSINESS WIRE)--Metabasis Therapeutics, Inc. (Nasdaq: MBRX) announced today that it has completed the four protocol-defined dose groups in its Phase 1b multiple-dose clinical trial evaluating the safety and tolerability of MB07811, its novel product candidate for the treatment of hyperlipidemia. Preliminary results from this ongoing trial indicate that MB07811 is safe and well tolerated at the doses studied, and based on these findings, the Company plans to explore the safety and tolerability of higher doses. In addition, the Company announced that the preliminary results from this trial suggest that MB07811 reduced fasting low-density lipoprotein (LDL) cholesterol levels, as well as fasting triglyceride (TG) levels.
